IDRA-21 – Kodiac biolabs

Plain-language summaryIntrigue 50 / 100

IDRA-21 is a benzothiadiazide ampakine developed at the University of Milan. It enhances AMPA receptor function and showed cognitive enhancement in primate studies. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

40/100

Clean AMPA desensitization probe with solid primate preclinical data but no human trials and pharma development abandoned in 2003

Look, IDRA-21 is one of those compounds that sits in an interesting but frustrating middle ground. It came out of Erminio Costa and Alessandro Guidotti’s group at the Nathan S. Kline Institute in the early 1990s, was licensed to Fidia Farmaceutici, and then quietly shelved in October 2003 without ever touching a human subject. That fact alone frames the whole conversation.

What we actually like about it is the mechanism specificity. Most AMPA positive allosteric modulators either block desensitization too aggressively, which creates excitotoxicity problems (cyclothiazide is the canonical example), or they work through racetam-class mechanisms that are poorly resolved at the molecular level. IDRA-21 sits in a cleaner position: it’s a partial negative allosteric modulator of desensitization, meaning it slows receptor deactivation without eliminating the safety brake entirely. The practical result in rodent and primate work is cognitive enhancement without the seizure liability or neurotoxic ceiling that limited the first-generation benzothiadiazines. Thats a meaningful pharmacological distinction, not just a marketing angle.

The primate behavioral data is the strongest card in this compounds hand. Getting to squirrel monkey cognitive studies is more than most preclinical-only compounds manage, and the passive avoidance and spatial learning effects were dose-consistent. The electrophysiological work also confirmed LTP enhancement in hippocampal preparations, which closes the loop between receptor-level pharmacology and the behavioral readouts in a reasonably satisfying way.

Here’s the thing though: the evidence base is frozen at around 2003. There’s no serious post-discontinuation research revival that we can point to, no multi-lab replication outside the NKI/Fidia ecosystem, and zero human signal of any kind. The AMPA receptor class has had a rough run in clinicals broadly. CX516 and CX614 from Cortex Pharmaceuticals largely disappointed, and the translational optimism of the late 1990s about ampakines for cognition and schizophrenia adjunction never materialized. IDRA-21 never got to fail in humans, but the class record isnt encouraging.

Where it retains real value is as a bench probe. If you’re studying AMPA receptor desensitization kinetics in vivo and you need an orally active tool that doesn’t kill your preparation via excitotoxicity, IDRA-21 is a genuinely useful reagent. It lets you dissociate desensitization modulation effects from the confounds you’d get with cyclothiazide or from the mechanistically fuzzy racetam profile. That’s honest probe value for a specific research question. We wouldn’t put it at the center of a research program, but as a tool compound in a circuit-level or synaptic plasticity study, it earns its place on the shelf.

Honestly, the compound deserves more attention than it gets from the nootropic community, but probably less excitement than serious AMPA receptor researchers might initially hope. No human data, development abandoned, class underperformed clinically. The partial modulation story is real and the primate work is credible, but this is a research curiosity with solid tool value, not a clinical candidate in waiting.

Novelty: 35
Mechanism promise: 55
In-category differentiation: 45
Evidence quality: 32
Translational signal: 22
Research bench value: 52

Rationale IDRA-21 earns its position primarily through its differentiated pharmacology within the ampakine class (partial desensitization modulation rather than full blockade, cleaner neurotoxicity profile than cyclothiazide, oral bioavailability with CNS penetration, primate-validated cognitive effects) and genuine bench utility as a selective AMPA-R tool; Fidia’s 2003 discontinuation without clinical entry, the complete absence of human data, and a 30-year-old literature base with no recent revival pull novelty and translational scores sharply down.

Benzothiadiazine-class positive allosteric modulator of AMPA-type glutamate receptors (ampakine)

A benzothiadiazine derivative developed at the Nathan S. Kline Institute as a partial negative allosteric modulator of AMPA receptor desensitization, distinguished from cyclothiazide and the racetam-class ampakines by partial intrinsic activity, prolonged duration of cognitive enhancement, absence of neurotoxicity at pharmacologically active doses, and oral bioavailability with central nervous system penetration in rodent and primate species.

Abstract

IDRA-21 (7-chloro-3-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine S,S-dioxide; CAS 22503-72-6; molecular formula C8H9ClN2O2S; molecular weight 232.69 g/mol) is a benzothiadiazine derivative that acts as a positive allosteric modulator of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) type glutamate receptors by attenuating receptor desensitization. The compound was synthesized and characterized at the Nathan S. Kline Institute for Psychiatric Research in Orangeburg, New York, under the direction of Erminio Costa and Alessandro Guidotti in the early 1990s, and was advanced through preclinical development by Fidia Farmaceutici SpA of Abano Terme, Italy, before discontinuation in October 2003 without entry into human clinical trials.

The mechanism of action is partial negative allosteric modulation of AMPA receptor desensitization, a pharmacological property that distinguishes IDRA-21 from the full modulators cyclothiazide and diazoxide. In cultured cerebellar granule neurons, IDRA-21 increases the sodium transient with a threshold concentration approximately 10-fold higher than cyclothiazide and an intrinsic activity significantly lower than that of cyclothiazide, producing a shorter-lasting calcium transient and, critically, complete absence of neurotoxicity at concentrations up to 100 micromolar in the presence of AMPA, compared to the severe neurotoxicity produced by cyclothiazide at 5 to 25 micromolar under identical conditions. The partial modulator mechanism therefore provides a wide therapeutic index between the concentrations that enhance cognition and those that produce excitotoxic neuronal injury.

The compound is a chiral molecule possessing one stereocenter at the 3-position of the benzothiadiazine ring. Enantiomeric resolution by Uzunov et al. (1995) using a custom chiral stationary phase demonstrated that the dextrorotatory (+)-IDRA-21 enantiomer is the pharmacologically active form in rat water maze performance, whereas the levorotatory (-)-enantiomer is devoid of activity at comparable doses. The racemate has been used in all published in vivo behavioral studies.

Preclinical cognitive enhancement has been documented across multiple species, behavioral paradigms, and impairment models. In rat passive avoidance and water maze tasks, racemic IDRA-21 at oral doses of 1 to 3 micromol/kg reverses cognitive deficits induced by alprazolam (a GABAergic positive modulator) and scopolamine (a muscarinic antagonist), with effect persisting for 3 to 4 hours after a single oral dose. In patas monkeys working in a complex operant learning task, IDRA-21 at 3 to 5.6 mg/kg orally antagonized alprazolam-induced learning deficits and was estimated to be approximately 10-fold more potent than aniracetam in this paradigm. In young adult and aged rhesus monkeys performing a delayed matching-to-sample task, oral IDRA-21 at 0.15 to 10 mg/kg produced robust improvements in task accuracy, with effects sustained to 48 hours after a single dose and accuracy on long-delay (most difficult) trials increased by up to 34 percent of vehicle at the individualized best dose. In young macaques performing a visual recognition memory task, oral IDRA-21 significantly improved performance on the longest delay condition.

A secondary pharmacological activity has been characterized: IDRA-21 negatively modulates NMDA receptor function in cultured cerebellar granule cells, with partial selectivity for NR2B-containing receptor assemblies. The NMDA receptor inhibition is neither competitive nor voltage-dependent and may contribute to the neuroprotective and cognitive profiles by tempering excessive NMDA receptor activation while potentiating AMPA receptor currents.

The principal safety concern identified in preclinical studies is the enhancement of ischemic neuronal injury. Yamada et al. (1998) demonstrated that IDRA-21 at 12 and 24 mg/kg orally increases CA1 hippocampal neuron loss following 10 minutes of global ischemia in rats, and that glutamate plus IDRA-21 produces AMPA receptor-dependent neurotoxicity in cultured hippocampal neurons. This finding has implications for any future clinical development in populations at risk of cerebrovascular events.

No human clinical trials have been conducted with IDRA-21. The compound was discontinued from development by Fidia Farmaceutici in October 2003. It remains available from multiple research-grade chemical suppliers at greater than 98 percent purity and is used as a reference compound in AMPA receptor pharmacology research and as a tool compound for the study of glutamatergic contributions to cognition and synaptic plasticity.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1436Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.